Has the Chinese Pharma Industry valuation changed over the past few years?

Investors are relatively neutral on the Chinese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 37.4x. The industry is trading close to its 3-year average PS ratio of 3.5x.

Which industries have driven the changes within the Chinese Healthcare industry?

There are no additional sub-industries under this industry.

Chinese (SSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 06 Jun 2026	CN¥2.5t	CN¥769.7b	CN¥69.7b	33.1x	36x	3.3x
Mon, 04 May 2026	CN¥2.9t	CN¥769.0b	CN¥69.9b	37.7x	41x	3.7x
Wed, 01 Apr 2026	CN¥2.9t	CN¥769.7b	CN¥68.3b	33.1x	42.2x	3.7x
Fri, 27 Feb 2026	CN¥2.9t	CN¥766.4b	CN¥69.0b	34.1x	42.5x	3.8x
Sun, 25 Jan 2026	CN¥3.0t	CN¥765.2b	CN¥68.3b	35.6x	44.6x	4x
Tue, 23 Dec 2025	CN¥3.0t	CN¥766.3b	CN¥68.2b	33.6x	44.4x	3.9x
Thu, 20 Nov 2025	CN¥3.1t	CN¥766.3b	CN¥68.2b	35.8x	45.6x	4.1x
Sat, 18 Oct 2025	CN¥3.2t	CN¥770.0b	CN¥68.3b	34.8x	46.3x	4.1x
Mon, 15 Sep 2025	CN¥3.4t	CN¥770.4b	CN¥66.4b	36.3x	50.5x	4.4x
Wed, 13 Aug 2025	CN¥3.2t	CN¥780.6b	CN¥71.6b	35.6x	45.3x	4.2x
Fri, 11 Jul 2025	CN¥2.9t	CN¥780.0b	CN¥71.3b	32x	41.3x	3.8x
Sun, 08 Jun 2025	CN¥2.9t	CN¥780.7b	CN¥71.5b	32.6x	40.4x	3.7x
Tue, 06 May 2025	CN¥2.6t	CN¥785.8b	CN¥71.7b	29.4x	36.7x	3.4x
Thu, 03 Apr 2025	CN¥2.7t	CN¥801.6b	CN¥78.9b	29.7x	34.1x	3.4x
Sat, 01 Mar 2025	CN¥2.5t	CN¥800.7b	CN¥75.8b	28x	33.2x	3.1x
Mon, 27 Jan 2025	CN¥2.5t	CN¥800.2b	CN¥75.6b	27.3x	32.5x	3.1x
Wed, 25 Dec 2024	CN¥2.6t	CN¥799.8b	CN¥75.6b	30.4x	34.7x	3.3x
Fri, 22 Nov 2024	CN¥2.7t	CN¥799.8b	CN¥75.6b	31.1x	36.2x	3.4x
Sun, 20 Oct 2024	CN¥2.6t	CN¥799.3b	CN¥76.4b	28.4x	34.4x	3.3x
Tue, 17 Sep 2024	CN¥2.2t	CN¥798.6b	CN¥76.3b	24.6x	29.1x	2.8x
Thu, 15 Aug 2024	CN¥2.4t	CN¥805.5b	CN¥76.5b	27.8x	30.9x	2.9x
Sat, 13 Jul 2024	CN¥2.4t	CN¥804.8b	CN¥76.5b	28.2x	30.8x	2.9x
Mon, 10 Jun 2024	CN¥2.5t	CN¥805.6b	CN¥74.6b	27.5x	33.9x	3.1x
Wed, 08 May 2024	CN¥2.8t	CN¥821.4b	CN¥77.5b	32.4x	36.4x	3.4x
Fri, 05 Apr 2024	CN¥2.6t	CN¥828.6b	CN¥78.3b	28.3x	33.4x	3.2x
Sun, 03 Mar 2024	CN¥2.6t	CN¥831.7b	CN¥80.8b	26.3x	31.9x	3.1x
Tue, 30 Jan 2024	CN¥2.5t	CN¥830.7b	CN¥79.8b	26.8x	31.4x	3x
Thu, 28 Dec 2023	CN¥2.8t	CN¥827.7b	CN¥79.7b	29.7x	34.7x	3.3x
Sat, 25 Nov 2023	CN¥2.9t	CN¥819.4b	CN¥78.7b	32.4x	37.1x	3.6x
Mon, 23 Oct 2023	CN¥2.6t	CN¥825.0b	CN¥78.6b	30x	33.5x	3.2x
Wed, 20 Sep 2023	CN¥2.7t	CN¥824.6b	CN¥78.5b	31.1x	34.9x	3.3x
Fri, 18 Aug 2023	CN¥2.7t	CN¥815.0b	CN¥78.1b	32.8x	34.8x	3.3x
Sun, 16 Jul 2023	CN¥2.8t	CN¥811.0b	CN¥76.9b	31.1x	36.3x	3.4x
Tue, 13 Jun 2023	CN¥2.8t	CN¥809.7b	CN¥76.5b	32.6x	37.1x	3.5x


CN Market	-1.40%
Healthcare	-4.61%
Pharma	-4.54%
Pharma	-4.54%

Company	Last Price	7D	1Y	Valuation
000766 Tonghua Golden-Horse Pharmaceutical Industry CoLtd	CN¥24.70	6.6% +CN¥1.5b	6.5%	PE749.9x
600750 China Resources Jiangzhong PharmaceuticalLtd	CN¥25.92	3.5% +CN¥547.6m	11.9%	PE17.9x
600222 Henan Taloph Pharmaceutical StockLtd	CN¥8.70	11.7% +CN¥503.2m	50.8%	PE78.8x
605507 Guobang Pharma	CN¥15.90	3.9% +CN¥461.6m	9.2%	PE16.2x
600566 Hubei Jumpcan Pharmaceutical	CN¥27.99	1.7% +CN¥424.0m	2.2%	PE14.8x

Announcement • Jun 02

Haisco Pharmaceutical Group Receives U.S. FDA Marketing Approval For Cipepofol (CYPSEDO) Injection

Haisco Pharmaceutical Group has officially received marketing approval from the U.S. Food and Drug Administration (FDA) for Cipepofol (CYPSEDO) Injection, a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, becoming the first China-originated innovative intravenous anesthetic to enter the global market. Cipepofol (Chinese trade name: Sishuning) is China's first independently developed Class 1 innovative intravenous anesthetic with global independent intellectual property rights. It has been approved in China for sedation and anesthesia in non-tracheal intubation surgeries/procedures, induction and maintenance of general anesthesia, and sedation during mechanical ventilation in the intensive care unit. In September 2025, its approval was further expanded to include the induction and maintenance of general anesthesia in children and adolescents. The development of Cipepofol dates back to 2012. Haisco's R&D team tackled numerous challenges to refine the molecular structure. By introducing a chiral cyclopropyl group and conducting thousands of screenings and safety evaluations, they successfully developed a Class 1 new drug that demonstrated favorable efficacy and safety profiles. Results from clinical studies conducted both domestically and internationally showed that, while retaining the advantages of rapid onset and complete recovery, Cipepofol significantly reduced the incidence of intraoperative respiratory depression and cardiovascular adverse reactions, as well as injection pain. With a lower risk of respiratory depression, more stable hemodynamics, milder injection pain, and individualized care for elderly and pediatric patients, Cipepofol not only makes "comfortable treatment" more compassionate—directly addressing patients' desire for a pain-free anesthesia induction and reducing their fear of surgery—but also substantially enhances the comfort and safety of the diagnosis and treatment process on both physiological and psychological levels, while greatly improving the accuracy and success rate of physicians' diagnoses and treatments. In December 2020, Cipepofol was officially approved for marketing by the National Medical Products Administration (NMPA), ushering in a new chapter in clinical comfortable anesthesia. Subsequently, multiple indications were approved in succession, including induction of general anesthesia, fiberoptic bronchoscopy, and sedation during intensive care. In September 2025, the dosage and administration for the induction and maintenance of general anesthesia in children and adolescents were approved, further broadening its clinical application scenarios. As of May 2026, Cipepofol has been incorporated into the recommendations of over 20 guidelines and consensus documents, as well as into textbooks for higher education under China's 14th Five-Year Plan, and has been included in the National Reimbursement Drug List (NRDL). To date, it has been adopted by over 3,300 medical institutions, cumulatively benefiting more than 40 million patient visits. After receiving FDA clearance to conduct clinical trials in 2021, Cipepofol was granted a waiver for Phase II trials in the United States and advanced directly to pivotal Phase III trials. All clinical studies were completed in 2024, yielding superior results in a head-to-head comparison against the standard of care. In July 2025, the New Drug Application (NDA) for Cipepofol was formally accepted by the U.S. FDA. Haisco is actively advancing its commercialization in the United States and other regions through collaborations. The company will also consider initiating a marketing authorization application in Europe at an appropriate time.

Chinese (SSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Consensus EPS estimates fall by 35%, revenue upgraded

High number of new directors

Dividend increased to CN¥0.70

Zhangzhou Pientzehuang Pharmaceutical., Ltd., Annual General Meeting, Jun 26, 2026

Haisco Pharmaceutical Group Receives U.S. FDA Marketing Approval For Cipepofol (CYPSEDO) Injection

Guobang Pharma Ltd. (SHSE:605507) announces an Equity Buyback for CNY 200 million worth of its shares.

Now 22% overvalued

Dividend of CN¥0.20 announced

New major risk - Earnings quality

Investor sentiment improves as stock rises 15%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 16, 2026

Fujian Cosunter Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2026

First quarter 2026 earnings released: EPS: CN¥0.006 (vs CN¥0.004 in 1Q 2025)

Full year 2025 earnings released: CN¥0.079 loss per share (vs CN¥0.18 loss in FY 2024)

First quarter 2026 earnings released: EPS: CN¥0.11 (vs CN¥0.004 in 1Q 2025)

First quarter 2026 earnings released: EPS: CN¥1.32 (vs CN¥0.13 in 1Q 2025)